Key result
Higher serum CD147/EMMPRIN correlates with poorer long-term renal graft function and severe interstitial fibrosis.
Why the study?
The role of serum CD147/EMMPRIN in long-term renal graft function and renal biopsy lesions related to fibrosis and tubular atrophy was not well characterized.
Does serum CD147/EMMPRIN concentration correlate with long-term renal graft function and histopathological lesions in renal graft recipients?
Observational (n=49)
No
Does serum CD147/EMMPRIN concentration correlate with long-term renal graft function and histopathological lesions in renal graft recipients?
Effect estimate: R = -0.69
p-value: p=<0.05
Higher serum concentrations of CD147/EMMPRIN are associated with poorer long-term renal graft function and increased severity of interstitial fibrosis and tubular atrophy.
Supports CD147/EMMPRIN as candidate biomarker for graft surveillance; leaves open prospective validation and therapeutic relevance in renal transplantation.
Chronic kidney disease (CKD) is associated with renal fibrosis, and develops with the participation of fibroblasts and myofibroblasts from epithelial-to-mesenchymal transition (EMT). In cancer research, the key role of the glycoprotein CD147/EMMPRIN (extracellular matrix metalloproteinase inducer) in EMT has been proven. In this study, we evaluate how serum CD147/EMMPRIN affects long-term renal graft function and renal biopsy specimen lesions. In total, 49 renal graft recipients who had a renal biopsy within the last 18 months were retrospectively reviewed. At their most recent appointments, their serum concentrations of CD147/EMMPRIN and renal function were assessed. The occurrence of delayed graft function (DGF), estimated glomerular filtration rate (eGFR) at 1-year post-kidney transplantation (Tx) and the subsequent years of the follow-up period, and renal biopsy specimen lesions, mainly those related to renal fibrosis and tubular atrophy, were also evaluated. Results: CD147/EMMPRIN serum concentration correlated negatively with eGFR at the most recent appointment (ME 69 months) and with eGFR at 1 and 2 years after Tx (p < 0.05, R = −0.69, R = −0.39, and R = −0.40, respectively). CD147/EMMPRIN serum levels correlated positively with urine protein concentrations (p < 0.05, R = 0.73). A positive correlation was further found with the severity of renal biopsy specimen lesions such as interstitial fibrosis (CI), tubular atrophy (CT), double contours of the GBM (CG), mesangial matrix expansion (MM), and arteriolar hyalinosis (AH) (p < 0.05, R = 0.39, R = 0.29, R = 0.41, R = 0.32 and R = 0.40, respectively). Patients with a history of DGF had higher CD147/EMMPRIN serum concentrations (<0.05). Conclusions: CD147/EMMPRIN is linked to poorer long-term renal graft function. Additionally, a high serum concentration of CD147/EMMPRIN affects interstitial fibrosis tubular atrophy (IF/TA) lesions and proteinuria.
No takes yet. Share an insight, caveat, or question.
Nalewajska et al. (2022) conducted an observational in Renal graft recipients (n=49). Serum CD147/EMMPRIN concentration was evaluated on eGFR at the most recent appointment (median 69 months) (R = -0.69, p=<0.05). Higher serum CD147/EMMPRIN concentrations significantly correlated with poorer long-term renal graft function (R = -0.69) and more severe interstitial fibrosis and tubular atrophy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: